Last: | |||
Change: | Change(%): | ||
Volume: | Open: | ||
High: | Low: | ||
52Wk High: | 52Wk Low: |
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.